tetrathiomolybdate and Corneal-Diseases

tetrathiomolybdate has been researched along with Corneal-Diseases* in 2 studies

Other Studies

2 other study(ies) available for tetrathiomolybdate and Corneal-Diseases

ArticleYear
Kayser-Fleischer ring as the presenting sign of Wilson disease.
    American journal of ophthalmology, 2002, Volume: 133, Issue:6

    To describe a case in which the recognition by the ophthalmologist of Kayser-Fleischer rings played a crucial role in the diagnosis of Wilson disease (hepatolenticular degeneration).. Interventional case report.. An 18-year-old woman was found to have bilateral peripheral golden brown pigment deposits at the level of the Descemet membrane consistent with Kayser-Fleischer rings. She initially denied systemic symptoms.. The serum cerumoplasmin level of the patient was normal. Liver function tests were also normal. Further evaluations with 24-hour urine copper assay and liver biopsy were positive for Wilson disease. She underwent anticopper therapy and, 6 months later, reported improved concentration and balance. No appreciable change occurred in the Kayser-Fleischer rings.. Wilson disease occurs when a defective copper-transporting enzyme in the liver results in toxic copper accumulation in multiple organs. Because of the insidious nature of the disease, patients may not seek medical attention until severe irreversible damage has occurred. By diagnosis of Kayser-Fleischer rings, ophthalmologists may play a critical role in the early recognition and proper evaluation of such patients.

    Topics: Adolescent; Biopsy; Ceruloplasmin; Copper; Corneal Diseases; Descemet Membrane; Drug Therapy, Combination; Female; Hepatolenticular Degeneration; Humans; Liver Function Tests; Molybdenum; Zinc Acetate

2002
Regression of Kayser-Fleischer rings during oral zinc therapy: correlation with systemic manifestations of Wilson's disease.
    Cornea, 1996, Volume: 15, Issue:6

    Fourteen patients presenting with neuropsychiatric manifestations of Wilson's disease were treated with oral tetrathiomolybdate (TM) for 8 weeks followed by oral zinc (Zn) maintenance therapy. The patients were evaluated prospectively at baseline and at yearly intervals for up to 5 years by slit-lamp biomicroscopy and photography, quantitative neurologic and speech pathology examinations, 24-h urine copper collection, and a quantitative scoring of magnetic resonance imaging (MRI) of the brain. Kayser-Fleischer (KF) ring size decreased significantly during the 5-year study period (p < 0.0001). Although results of neurologic examination, speech pathology examination, and 24-h urine copper level analysis in symptomatic Wilson's disease patients improved during the study period, KF ring regression did not correlate with the improvement in these clinical parameters (p > 0.05). However, there was a correlation between MRI scores and KF ring regression (p = 0.02). Anticopper therapy with TM followed by zinc maintenance therapy is a safe and effective treatment for patients with neurologically symptomatic Wilson's disease. This treatment leads to reduction in KF ring size; however, KF ring reduction is not a good predictor of clinical improvement for patients with neuropsychiatric manifestations of Wilson's disease.

    Topics: Administration, Oral; Adolescent; Adult; Brain Diseases; Copper; Cornea; Corneal Diseases; Female; Hepatolenticular Degeneration; Humans; Magnetic Resonance Imaging; Male; Molybdenum; Prospective Studies; Zinc

1996